Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer

National Institute for Clinical Excellence
Record ID 32003000500
English
Authors' objectives:

To provide guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer.

Authors' recommendations: Guidance: 1.1 Oral therapy with either capecitabine or tegafur with uracil (in combination with folinic acid) is recommended as an option for the first-line treatment of metastatic colorectal cancer. 1.2 The choice of regimen (intravenous fluorouracil/folinic acid [5-FU/FA] or one of the oral therapies) should be made jointly by the individual and the clinician(s) responsible for treatment. The decision should be made after an informed discussion between the clinician(s) and the patient; this discussion should take into account contraindications and the side-effect profile of the agents as well as the clinical condition and preferences of the individual. 1.3 The use of capecitabine or tegafur with uracil to treat metastatic colorectal cancer should be supervised by oncologists who specialise in colorectal cancer.
Authors' methods: Systematic review
Details
Project Status: Completed
URL for project: http://www.nice.org.uk/cat.asp?c=70054
Year Published: 2003
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Antimetabolites, Antineoplastic
  • Antineoplastic Combined Chemotherapy Protocols
  • Colorectal Neoplasms
  • Deoxycytidine
  • Prodrugs
  • Tegafur
  • Uracil
Contact
Organisation Name: National Institute for Clinical Excellence
Contact Address: MidCity Place, 71 High Holborn, London WC1V 6NA, UK. Tel: +44 020 7067 5800; Fax: +44 020 7067 5801
Contact Name: nice@nice.nhs.uk
Contact Email: nice@nice.nhs.uk
Copyright: National Institute for Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.